|
Amyotrophic Lateral Sclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both L3MBTL1 and SET domain-containing protein 8 were upregulated in the central nervous systems of mouse models of amyotrophic lateral sclerosis and human patients with amyotrophic lateral sclerosis/frontotemporal dementia.
|
31061493 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results indicate that SET8 may be a novel target for colorectal cancer therapy.
|
30881512 |
2019 |
|
Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on our results, we suggest that SETD8 has a critical role mediating Group 3 MB tumorigenesis.
|
30626740 |
2019 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
By contrast, SET8 overexpression aggravated the glycolytic alterations and tumor progression.
|
30952833 |
2019 |
|
Pick Disease of the Brain
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both L3MBTL1 and SET domain-containing protein 8 were upregulated in the central nervous systems of mouse models of amyotrophic lateral sclerosis and human patients with amyotrophic lateral sclerosis/frontotemporal dementia.
|
31061493 |
2019 |
|
Childhood Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on our results, we suggest that SETD8 has a critical role mediating Group 3 MB tumorigenesis.
|
30626740 |
2019 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on our results, we suggest that SETD8 has a critical role mediating Group 3 MB tumorigenesis.
|
30626740 |
2019 |
|
Frontotemporal dementia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both L3MBTL1 and SET domain-containing protein 8 were upregulated in the central nervous systems of mouse models of amyotrophic lateral sclerosis and human patients with amyotrophic lateral sclerosis/frontotemporal dementia.
|
31061493 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results indicate that SET8 may be a novel target for colorectal cancer therapy.
|
30881512 |
2019 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the role of SETD8 in glioma progression has not been investigated.
|
29487005 |
2018 |
|
Squamous cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
We demonstrate that shRNA-mediated or pharmacological inhibition of SETD8 selectively inhibits LUSC growth.
|
30127402 |
2018 |
|
Papillary thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, KMT5A may be a novel oncogenic factor, specifically a regulator for lipid metabolism in papillary thyroid carcinoma.
|
29512765 |
2018 |
|
Tuberculosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, augmenting host immune responses against Mycobacterium tuberculosis by harnessing the SET8-NQO1/TRXR1 axis with its specific and potent inhibitors could lead to promising host-directed therapeutic adjuvants for tuberculosis treatment.
|
28931237 |
2017 |
|
Anemia, severe
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Erythroid Setd8 deletion results in embryonic lethality from severe anemia due to impaired erythroblast survival and proliferation.
|
29186677 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Low SET8 protein levels were negatively associated with tumor-node-metastasis staging in patients with ccRCC according to the size of tumor and lymph node metastases.
|
29250163 |
2017 |
|
High-Risk Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In pre-clinical xenograft NB models, genetic or pharmacological (UNC0379) SETD8 inhibition conferred a significant survival advantage, providing evidence for SETD8 as a therapeutic target in NB.
|
28073004 |
2017 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CRISPR/Cas9-mediated heterozygous deletion of CDKN1A (encoding p21) or SET8 in melanoma cells demonstrated that the rereplication-mediated cytotoxicity of pevonedistat is mediated through preventing the degradation of p21 and SET8 and is essential for melanoma suppression in nude mice.
|
27333051 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our data indicated that SET8 was a new target for ESCC therapy.
|
27605386 |
2016 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
SET8 expression was significantly higher in breast tumor tissue than in paired adjacent normal tissue.
|
27144429 |
2016 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Mounting evidence suggested that histone H4K20-specific methyltransferase SET8 is required to maintain the malignant phenotype of various cancer types; however, the role of SET8 in mediating tumor metastasis in prostate cancer (PCa) has remained elusive.
|
26717907 |
2016 |
|
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SET8 expression is associated with overall survival in gastric cancer.
|
26634528 |
2015 |
|
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SET8 expression is associated with overall survival in gastric cancer.
|
26634528 |
2015 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrated that SETD8 rs16917496 C/T polymorphism was associated with decreased risk of developing pediatric ALL in Zahedan, southeast Iran.
|
25048968 |
2014 |
|
Lymphoma, Non-Hodgkin
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Prognostic value of microRNA 502 binding site SNP in the 3'-untranslated region of the SET8 gene in patients with non-Hodgkin's lymphoma.
|
25343552 |
2014 |
|
Adult Non-Hodgkin Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Prognostic value of microRNA 502 binding site SNP in the 3'-untranslated region of the SET8 gene in patients with non-Hodgkin's lymphoma.
|
25343552 |
2014 |